{"id":"risperidone-low-dose","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Weight gain"},{"rate":"15-25","effect":"Sedation"},{"rate":"10-20","effect":"Akathisia"},{"rate":"40-50","effect":"Prolactin elevation"},{"rate":"10-15","effect":"Extrapyramidal symptoms"},{"rate":"5-10","effect":"Orthostatic hypotension"},{"rate":"15-25","effect":"Metabolic syndrome"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Risperidone is an atypical antipsychotic that antagonizes dopamine D2 receptors in the mesolimbic and mesocortical pathways, reducing positive symptoms of psychosis such as hallucinations and delusions. It also blocks serotonin 5-HT2A receptors, which contributes to its efficacy in treating negative symptoms and mood disturbances. The low-dose formulation provides therapeutic benefit with potentially reduced extrapyramidal side effects compared to higher doses.","oneSentence":"Risperidone blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:25.423Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder (acute mania and maintenance)"},{"name":"Irritability associated with autism spectrum disorder"},{"name":"Aggression and behavioral disturbances in dementia"}]},"trialDetails":[{"nctId":"NCT06768944","phase":"PHASE2","title":"Subjective Experience Following Psilocybin","status":"NOT_YET_RECRUITING","sponsor":"University of Calgary","startDate":"2026-04","conditions":"Investigating the Importance of the Subjective Psychedelic Experience","enrollment":128},{"nctId":"NCT01499563","phase":"PHASE2","title":"Study of a Novel Antipsychotic ITI-007 in Schizophrenia","status":"COMPLETED","sponsor":"Intra-Cellular Therapies, Inc.","startDate":"2011-12","conditions":"Schizophrenia","enrollment":335},{"nctId":"NCT04940039","phase":"PHASE4","title":"A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2021-07-22","conditions":"Schizophrenia","enrollment":93},{"nctId":"NCT03227562","phase":"PHASE3","title":"Is Initial Response to Low Dose Risperidone Predictive for Outcome in Anxiety?","status":"TERMINATED","sponsor":"Marion Trousselard","startDate":"2017-09-01","conditions":"Anxiety State","enrollment":120},{"nctId":"NCT03451734","phase":"","title":"Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients","status":"COMPLETED","sponsor":"Central South University","startDate":"2018-01-23","conditions":"Schizophrenia, Metabolic Syndrome","enrollment":2000},{"nctId":"NCT02435095","phase":"PHASE4","title":"Antipsychotic Induced Structural and Functional Brain Changes","status":"TERMINATED","sponsor":"RWTH Aachen University","startDate":"2015-05","conditions":"Schizophrenia","enrollment":174},{"nctId":"NCT02063945","phase":"PHASE4","title":"Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders","status":"TERMINATED","sponsor":"Sheba Medical Center","startDate":"2017-02-01","conditions":"Attention Deficit/Hyperactivity Disorder, Oppositional Defiant Disorder, Conduct Disorder","enrollment":5},{"nctId":"NCT04076371","phase":"NA","title":"The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Beijing HuiLongGuan Hospital","startDate":"2012-01","conditions":"Schizophrenia","enrollment":1640},{"nctId":"NCT01878513","phase":"NA","title":"Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2009-09-23","conditions":"Schizophrenia, Schizoaffective Disorder, Psychotic Disorder Not Otherwise Specified","enrollment":88},{"nctId":"NCT02661347","phase":"NA","title":"Transcranial Direct Current Stimulation for Hallucinations in First-Episode Schizophrenia","status":"WITHDRAWN","sponsor":"Northwell Health","startDate":"2016-02","conditions":"Schizophrenia, Schizophreniform, Schizoaffective Disorder","enrollment":""},{"nctId":"NCT02687984","phase":"PHASE1","title":"PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2016-02","conditions":"Schizophrenia","enrollment":44},{"nctId":"NCT02964923","phase":"","title":"Genes Polymorphisms and Metabolic Effects of the Second Generation Antipsychotic Drugs in Patients With Schizophrenia","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2016-04","conditions":"Schizophrenia","enrollment":300},{"nctId":"NCT02768649","phase":"PHASE1","title":"Single Ascending Dose Study of RBP-7000","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2011-04","conditions":"Schizophrenia","enrollment":45},{"nctId":"NCT00099983","phase":"PHASE2","title":"Risperidone Treatment for Military Service Related Chronic Post Traumatic Stress Disorder","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2006-10","conditions":"Stress Disorders, Post-Traumatic","enrollment":296},{"nctId":"NCT02137616","phase":"NA","title":"Antipsychotic to Treat Psychosis Syndrome","status":"UNKNOWN","sponsor":"Central South University","startDate":"2012-06","conditions":"Psychotic Disorders","enrollment":300},{"nctId":"NCT00576732","phase":"PHASE4","title":"A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-12","conditions":"Autistic Disorder, Autism","enrollment":96},{"nctId":"NCT00722176","phase":"PHASE2","title":"Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020","status":"COMPLETED","sponsor":"BioLineRx, Ltd.","startDate":"2008-06","conditions":"Schizophrenia","enrollment":220},{"nctId":"NCT00567710","phase":"PHASE2","title":"A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study","status":"COMPLETED","sponsor":"BioLineRx, Ltd.","startDate":"2008-07","conditions":"Schizophrenia","enrollment":360},{"nctId":"NCT00998608","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Risperidone Versus Risperidone Plus Low Dose of Haloperidol in the Treatment of Schizophrenia","status":"TERMINATED","sponsor":"Kaohsiung Kai-Suan Psychiatric Hospital","startDate":"2007-08","conditions":"Schizophrenia","enrollment":88},{"nctId":"NCT00305474","phase":"PHASE4","title":"Identification and Treatment of the Liability to Develop Schizophrenia","status":"UNKNOWN","sponsor":"Central South University","startDate":"2003-12","conditions":"Schizophrenia","enrollment":100},{"nctId":"NCT00633802","phase":"NA","title":"Low-Dose Risperidone Treatment for Subjects Suffering From Borderline Personality Disorder","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2004-04","conditions":"Borderlone Personality Disorder","enrollment":30},{"nctId":"NCT00159081","phase":"PHASE4","title":"One Year Drug Treatment in First-Episode Schizophrenia","status":"COMPLETED","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2000-11","conditions":"Schizophrenia","enrollment":159}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Risperidone low dose","genericName":"Risperidone low dose","companyName":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","companyId":"johnson-johnson-pharmaceutical-research-development-l-l-c","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Risperidone blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar I disorder (acute mania and maintenance), Irritability associated with autism spectrum disorder.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}